The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia

Halcox, Julian P.J, Nour, Khaled R.A., Zalos, Gloria, Mincemoyer, Rita, Waclawiw, Myron, Rivera, Candido E., Willie, Gerogia, Ellahham, Samer and Quyyumi, Arshed A. 2002. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. Journal of the American College of Cardiology 40 (7) , pp. 1232-1240. 10.1016/s0735-1097(02)02139-3

Full text not available from this repository.

Abstract

OBJECTIVE: We studied the effects of sildenafil, a phosphodiesterase 5 inhibitor, on coronary and peripheral vascular function, platelet activation, and myocardial ischemia. BACKGROUND: Nitric oxide vasodilates and inhibits platelet activation by generating cyclic guanosine 5'-monophosphate, which is metabolized by phosphodiesterase type 5. METHODS: The effect of oral sildenafil on resting coronary vascular tone, endothelium-dependent and -independent function and platelet activation was measured in 24 patients. An additional 24 patients with coronary artery disease (CAD) and ischemia during exercise, and 12 control subjects received either 100 mg of sildenafil, 10 mg of isosorbide dinitrate (ISDN) or placebo during exercise on three separate days in a randomized, double-blind manner. Flow-mediated dilation of the brachial artery was measured, and CAD patients underwent treadmill exercise testing. RESULTS: Sildenafil (100 mg) vasodilated epicardial coronary arteries (+6.9 +/- 1.3%, p < 0.0001). Coronary epicardial and microvascular responses with acetylcholine and cold-pressor testing improved, with a greater enhancement in patients with CAD and endothelial dysfunction. Verapamil responses were unchanged. Both resting and adenosine diphosphate-stimulated platelet IIb/IIIa receptor activation was inhibited by sildenafil (p < 0.05). Brachial arteries dilated in response to sildenafil in controls. Peak flow-mediated dilation was similar, but the duration of hyperemia was prolonged after sildenafil administration (p < 0.001). Compared with placebo, ISDN improved myocardial ischemia during exercise (p < 0.05), whereas the effect of sildenafil was intermediate between the two. CONCLUSIONS: Sildenafil dilates epicardial coronary arteries, improves endothelial dysfunction and inhibits platelet activation in patients with CAD. It has an intermediate effect on myocardial ischemia compared with ISDN and placebo.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Additional Information:	Full Text Sources Ingenta plc Gale Databases ProQuest Other Literature Sources COS Scholar Universe Labome Researcher Resource - ExactAntigen/Labome Access more work from the authors - ResearchGate Miscellaneous NCI CPTAC Assay Portal NCI CPTAC Assay Portal
Publisher:	Elsevier
ISSN:	0735-1097
Date of Acceptance:	27 June 2002
Last Modified:	02 Nov 2015 11:36
URI:	https://orca.cardiff.ac.uk/id/eprint/71111

Citation Data

Cited 248 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item